Endothelial Protection in Post COVID-19 Patients With Sulodexide
Status:
Not yet recruiting
Trial end date:
2022-11-12
Target enrollment:
Participant gender:
Summary
This is a Prospective, multicenter, randomized (1:1, placebo use) trial with a parallel-group
design to assess if the use of sulodexide influences serum levels of biomarkers for
endothelial dysfunction on convalescent COVID-19 patients who suffered a moderate (or more
severe) clinical presentation and have chronic comorbidities of high risk for endothelial
dysfunction.
The recruitment period is estimated at 6 months. The follow-up period of all participants
will be 8 weeks.
The participant will receive according to group allocation after randomization
1. study group: sulodexide oral dose of 250LRU capsule bid for 8 weeks.
2. control group: placebo oral dose of 1 capsule bid for 8 weeks.
Participants in both groups will continue the standard of care recommended by national
healthcare guidelines for each Country, including any concomitant medication indicated by
their primary physician.